Video Insights
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
Myelofibrosis Awareness Day is marked on September 20th each year.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
The meeting will be held September 6-9, 2023, in Houston, Texas.
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Dr. Gagelmann outlines the challenges that he sees in Europe and across the globe for young researchers and clinicians.
The panelists highlight key data presented at ASCO 2023.
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
The study showed that the infusion of obe-cel resulted in very low rates of Grade 3 or higher CRS and ICANS.
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Dr. Gagelmann outlines key highlights of the session, his presentation and what he hopes attendees learned from the session.
A specific subset of antibiotics "were particularly bad" for the microbiome and were associated with poor survival.
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Dr. Winer discusses emavusertib, an orally bioavailable, reversible inhibitor of IRAK4.
Dr. Nabhan, who hosts The HemOnc Pulse, discusses the podcast and what he hopes listeners gain from it at ASCO 2023.
Dr. Krecak presented the research during the 2023 EHA Congress.
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Dr. Nabhan also speaks about his next book, which is expected to be released in fall 2024.
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Dr. Thijssen served as chair for the Young EHA session on senescence, aging, and cell death.
The panel considers triplet versus quadruplet therapy for myeloma induction.
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
The response rates seen with talquetamab in the trial were "very impressive," Dr. Schinke said.
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
The study evaluated teclistamab in patients with relapsed or refractory multiple myeloma.
Dr. Rutherford and colleagues hypothesized there would be no impact on PFS when imaging was performed less frequently.
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
The real-world analysis of racial disparities in CLL accounted for the treatment that patients received.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Knowledge Hubs
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
